Dr. Ingmar Gorman is a co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. Dr. Gorman received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on a Phase 3 clinical trial of MDMA-assisted Psychotherapy for PTSD and is a study therapist on the same study. Dr. Gorman has published on the topics of psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration.